Tempus AI, Inc. Class A (TEM)

In Q1 2026, Tempus AI reported revenue of $348.1 million, a 36.1% year-over-year increase, but posted a wider-than-expected GAAP net loss. A short-seller report in May 2025 alleged aggressive accounting practices, leading to a stock price drop and subsequent lawsuits. Tempus AI announced oncology collaborations with Merck & Co. and Gilead Sciences, and was named to TIME's list of the 10 Most Influential Health and Life Science Companies of 2026. Tempus announced a proposed offering of convertible senior notes to optimize its capital structure and reduce interest expense. Tempus AI's stock has experienced significant volatility over the past 12 months.

While there isn't explicit information detailing demand seasonality for Tempus AI's specific products and services, the company experienced "typical seasonal outflows including bonuses and timing of payables" impacting cash flow from operations in the first quarter of 2026. The demand for Tempus AI's services, particularly in diagnostics and data applications, has been described as robust.

Tempus AI, Inc., founded in 2015, is a health technology company that integrates genomics, data, and AI to advance precision medicine. The company assists physicians in making personalized treatment decisions, particularly in oncology, genomics, and precision medicine, by leveraging clinical and molecular data. Its business model includes Genomics, Data, and AI Applications.

Tempus AI, Inc. is headquartered in Chicago, Illinois, and primarily operates in the United States. Approximately 50% of U.S. oncologists order its tests or contribute data, and around 65% of U.S. academic medical centers are connected to Tempus. Internationally, Tempus has expanded its reach through a joint venture with SoftBank in June 2024, forming SB Tempus in Japan.

Tempus AI was named to TIME's list of the 10 Most Influential Health and Life Science Companies of 2026. However, a short-seller report in May 2025 alleged AI-washing and aggressive accounting practices, leading to a securities lawsuit. In March 2026, two lawsuits were filed against Tempus AI alleging violations of the Illinois Genetic Information Privacy Act.

Tempus AI's ownership includes insiders, institutional investors, and public companies/individual investors. CEO Eric Lefkofsky is the largest individual shareholder, holding approximately 27% of the company's shares. Major institutional holders include The Vanguard Group, ARK Investment Management LLC, Baillie Gifford & Co., BlackRock, Inc., SoftBank Group Corp., Franklin Templeton, and T. Rowe Price.